Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...
The high-profile obesity drug developer priced the biotech sector’s biggest offering since 2022 and will use the proceeds to ...
The Fremont company sold extra shares at the top of its proposed range, and the stock jumped more than 30% in initial trading ...
Investor's Business Daily on MSN
Four biotech stocks near buy points as earnings season kicks in
Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...
Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...
Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...
-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...
For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...
Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
9hon MSN
Windlas Biotech announces Rs 47 crore buyback at Rs 1,000/share; sets April 24 as record date
Windlas Biotech approved a Rs 47 crore share buyback at Rs 1,000 per share via the tender route, with April 24 set as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results